Litcius/Paper detail

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

Varun Sasisekharan, Niharika Pentakota, Akila Jayaraman, Kannan Tharakaraman, Gerald N. Wogan, Uma Narayanasami

2021Proceedings of the National Academy of Sciences30 citationsDOIOpen Access PDF

Abstract

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.

Topics & Concepts

ImmunologyImmune systemPandemicCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyVirologyAntigenTiterMedicineDisease2019-20 coronavirus outbreakInfectious disease (medical specialty)Internal medicineOutbreakSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies